Exemple de rapport Quest

COMMENTS: FASTING:YES Test Name In Range Out Of Range Reference Range Lab IRON, TIBC AND FERRITIN PANEL IRON AND TOTAL IRON NL1 BINDING CAPACITY IRON, TOTAL 170 50-180 mcg/dL IRON BINDING CAPACITY 317 250-425 mcg/dL (calc) % SATURATION 54 H 20-48 % (calc) FERRITIN 248 38-380 ng/mL NL1 LIPID PANEL, STANDARD CHOLESTEROL, TOTAL 237 H <200 mg/dL NL1 HDL CHOLESTEROL 69 > OR = 40 mg/dL NL1 TRIGLYCERIDES 78 <150 mg/dL NL1 LDL-CHOLESTEROL 150 H mg/dL (calc) NL1 Reference range: <100 Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with > or = 2 CHD risk factors. LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164) CHOL/HDLC RATIO 3.4 <5.0 (calc) NL1 NON HDL CHOLESTEROL 168 H <130 mg/dL (calc) NL1 For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 2.7 mg/L NL1 Reference Range Optimal <1.0 Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87. For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk. 1.0-3.0 Average relative cardiovascular risk. 3.1-10.0 Higher relative cardiovascular risk. Consider retesting in 1 to 2 weeks to exclude a benign transient elevation in the baseline CRP value secondary to infection or inflammation. >10.0 Persistent elevation, upon retesting, may be associated with infection and inflammation. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the SAMPLE NO CODE Report Status: Final FICTIONAL SAMPLE - NOT VALID FOR MEDICAL USE SMITH, MICHAEL Page 1 of 5 Patient Information MICHAEL SMITH DOB: 01/15/1974 AGE: 52 Gender: M Patient ID: SAMPLE-260216 Phone: 207-555-0142 Specimen Information Specimen: SAMPLE-001 Requisition: SAMPLE-002 Lab Ref: SAMPLE-REPORT Collected: 02/16/2026 Status: Final Client Information SAMPLE ACCOUNT NOT ACTIVE 100 Sample Street Presque Isle, ME 04769 Client #: SAMPLE-001 SPECIMEN: SAMPLE-001 FICTIONAL SAMPLE - IDENTIFIERS REPLACED 1 / 5

American Heart Association. Circulation 2003; 107(3): 499-511. HOMOCYSTEINE 8.5 < or = 15.2 umol/L NL1 Homocysteine is increased by functional deficiency of folate or vitamin B12. Testing for methylmalonic acid differentiates between these deficiencies. Other causes of increased homocysteine include renal failure, folate antagonists such as methotrexate and phenytoin, and exposure to nitrous oxide. Selhub J, et al., Ann Intern Med. 1999;131(5):331-9. APOLIPOPROTEIN B 123 H <90 mg/dL AMD Reference Range: <90 Risk Category: Optimal <90 Moderate 90-129 High > or = 130 A desirable treatment target may be <80 mg/dL or lower depending on the risk category of the patient including patients on lipid lowering therapies, patients with ASCVD, diabetes with >1 risk factors, Stage 3 or greater CKD with albuminuria, or heterozygous familial hypercholesterolemia. ApoB relative risk category cut points are based AACE/ACE and ACC/AHA recommendations. (Grundy SM, et al. 2019.doi:10.1016/j.jacc.2018.11.002; Handelsman Y, et al. 2020. doi:10.4158/CS-2020-0490). COMPREHENSIVE METABOLIC NL1 PANEL GLUCOSE 108 H 65-99 mg/dL Fasting reference interval For someone without known diabetes, a glucose value between 100 and 125 mg/dL is consistent with prediabetes and should be confirmed with a follow-up test. UREA NITROGEN (BUN) 16 7-25 mg/dL CREATININE 0.99 0.70-1.30 mg/dL EGFR 89 > OR = 60 mL/min/1.73m2 BUN/CREATININE RATIO SEE NOTE: 6-22 (calc) Not Reported: BUN and Creatinine are within reference range. SODIUM 141 135-146 mmol/L POTASSIUM 4.2 3.5-5.3 mmol/L CHLORIDE 103 98-110 mmol/L CARBON DIOXIDE 27 20-32 mmol/L CALCIUM 9.5 8.6-10.3 mg/dL PROTEIN, TOTAL 7.2 6.1-8.1 g/dL ALBUMIN 4.5 3.6-5.1 g/dL GLOBULIN 2.7 1.9-3.7 g/dL (calc) SAMPLE NO CODE Report Status: Final FICTIONAL SAMPLE - NOT VALID FOR MEDICAL USE SMITH, MICHAEL Page 2 of 5 Patient Information MICHAEL SMITH DOB: 01/15/1974 AGE: 52 Gender: M Patient ID: SAMPLE-260216 Phone: 207-555-0142 Specimen Information Specimen: SAMPLE-001 Requisition: SAMPLE-002 Lab Ref: SAMPLE-REPORT Collected: 02/16/2026 Status: Final Client Information SAMPLE ACCOUNT NOT ACTIVE 100 Sample Street Presque Isle, ME 04769 Client #: SAMPLE-001 SPECIMEN: SAMPLE-001 FICTIONAL SAMPLE - IDENTIFIERS REPLACED 2 / 5

ALBUMIN/GLOBULIN RATIO 1.7 1.0-2.5 (calc) BILIRUBIN, TOTAL 1.3 H 0.2-1.2 mg/dL ALKALINE PHOSPHATASE 49 35-144 U/L AST 24 10-35 U/L ALT 23 9-46 U/L HEMOGLOBIN A1c 5.7 H <5.7 % NL1 For someone without known diabetes, a hemoglobin A1c value between 5.7% and 6.4% is consistent with prediabetes and should be confirmed with a follow-up test. For someone with known diabetes, a value <7% indicates that their diabetes is well controlled. A1c targets should be individualized based on duration of diabetes, age, comorbid conditions, and other considerations. This assay result is consistent with an increased risk of diabetes. Currently, no consensus exists regarding use of hemoglobin A1c for diagnosis of diabetes for children. URIC ACID 5.5 4.0-8.0 mg/dL NL1 Therapeutic target for gout patients: <6.0 mg/dL GGT 48 3-85 U/L NL1 LIPOPROTEIN (a) 139 H <75 nmol/L AMD Risk Category Optimal < 75 nmol/L Moderate 75 - 125 nmol/L High > 125 nmol/L Cardiovascular event risk category cut points (optimal, moderate, high) are based on Tsimika S. JACC 2017;69:692-711. CBC (H/H, RBC, INDICES, NL1 WBC, PLT) WHITE BLOOD CELL COUNT 7.1 3.8-10.8 Thousand/uL RED BLOOD CELL COUNT 5.31 4.20-5.80 Million/uL HEMOGLOBIN 16.2 13.2-17.1 g/dL HEMATOCRIT 49.2 39.4-51.1 % MCV 92.7 81.4-101.7 fL MCH 30.5 27.0-33.0 pg MCHC 32.9 31.6-35.4 g/dL RDW 12.7 11.0-15.0 % PLATELET COUNT 283 140-400 Thousand/uL MPV 10.5 7.5-12.5 fL INSULIN 6.3 uIU/mL NL1 Reference Range < or = 18.4 Risk: Optimal < or = 18.4 Moderate NA SAMPLE NO CODE Report Status: Final FICTIONAL SAMPLE - NOT VALID FOR MEDICAL USE SMITH, MICHAEL Page 3 of 5 Patient Information MICHAEL SMITH DOB: 01/15/1974 AGE: 52 Gender: M Patient ID: SAMPLE-260216 Phone: 207-555-0142 Specimen Information Specimen: SAMPLE-001 Requisition: SAMPLE-002 Lab Ref: SAMPLE-REPORT Collected: 02/16/2026 Status: Final Client Information SAMPLE ACCOUNT NOT ACTIVE 100 Sample Street Presque Isle, ME 04769 Client #: SAMPLE-001 SPECIMEN: SAMPLE-001 FICTIONAL SAMPLE - IDENTIFIERS REPLACED 3 / 5

High >18.4 Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on Insulin Reference Interval studies performed at Quest Diagnostics in 2022. SAMPLE NO CODE Report Status: Final FICTIONAL SAMPLE - NOT VALID FOR MEDICAL USE SMITH, MICHAEL Page 4 of 5 Patient Information MICHAEL SMITH DOB: 01/15/1974 AGE: 52 Gender: M Patient ID: SAMPLE-260216 Phone: 207-555-0142 Specimen Information Specimen: SAMPLE-001 Requisition: SAMPLE-002 Lab Ref: SAMPLE-REPORT Collected: 02/16/2026 Status: Final Client Information SAMPLE ACCOUNT NOT ACTIVE 100 Sample Street Presque Isle, ME 04769 Client #: SAMPLE-001 SPECIMEN: SAMPLE-001 FICTIONAL SAMPLE - IDENTIFIERS REPLACED 4 / 5

Endocrinology Test Name Result Reference Range Lab VITAMIN D,25-OH,TOTAL,IA 41 30-100 ng/mL NL1 Vitamin D Status 25-OH Vitamin D: Deficiency: <20 ng/mL Insufficiency: 20 - 29 ng/mL Optimal: > or = 30 ng/mL For 25-OH Vitamin D testing on patients on D2-supplementation and patients for whom quantitation of D2 and D3 fractions is required, the QuestAssureD(TM) 25-OH VIT D, (D2,D3), LC/MS/MS is recommended: order code 92888 (patients >2yrs). For additional information, please refer to http://education.QuestDiagnostics.com/faq/FAQ199 (This link is being provided for informational/ educational purposes only.) Physician Comments: PERFORMING SITE: AMD QUEST DIAGNOSTICS/NICHOLS CHANTILLY, 14225 NEWBROOK DRIVE, CHANTILLY, VA 20151-2228 Laboratory Director: PATRICK W. MASON,MD,PHD, CLIA: 49D0221801 NL1 QUEST DIAGNOSTICS LLC, 200 FOREST STREET, MARLBOROUGH, MA 01752-3023 Laboratory Director: SALIM E KABAWAT,MD, CLIA: 22D0076229 SAMPLE NO CODE Report Status: Final FICTIONAL SAMPLE - NOT VALID FOR MEDICAL USE SMITH, MICHAEL Page 5 of 5 Patient Information MICHAEL SMITH DOB: 01/15/1974 AGE: 52 Gender: M Patient ID: SAMPLE-260216 Phone: 207-555-0142 Specimen Information Specimen: SAMPLE-001 Requisition: SAMPLE-002 Lab Ref: SAMPLE-REPORT Collected: 02/16/2026 Status: Final Client Information SAMPLE ACCOUNT NOT ACTIVE 100 Sample Street Presque Isle, ME 04769 Client #: SAMPLE-001 SPECIMEN: SAMPLE-001 FICTIONAL SAMPLE - IDENTIFIERS REPLACED 5 / 5 PATIENT ADDRESS: FICTIONAL SAMPLE MICHAEL SMITH - 100 Sample Street Presque Isle, ME 04769